NASDAQ:SIBN - Nasdaq - US8257041090 - Common Stock - Currency: USD
19.06
+0.57 (+3.08%)
The current stock price of SIBN is 19.06 USD. In the past month the price increased by 9.1%. In the past year, price increased by 43.52%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.02 | 233.03B | ||
ISRG | INTUITIVE SURGICAL INC | 73.04 | 200.02B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.09 | 152.13B | ||
SYK | STRYKER CORP | 30.57 | 146.41B | ||
MDT | MEDTRONIC PLC | 15.82 | 111.58B | ||
BDX | BECTON DICKINSON AND CO | 12.14 | 49.02B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.91 | 45.62B | ||
IDXX | IDEXX LABORATORIES INC | 45.81 | 42.32B | ||
RMD | RESMED INC | 27.5 | 36.61B | ||
DXCM | DEXCOM INC | 51.96 | 33.62B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.55 | 32.76B | ||
STE | STERIS PLC | 26.08 | 23.93B |
SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 349 full-time employees. The company went IPO on 2018-10-17. The firm specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The firm's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The firm's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
SI-BONE INC
471 El Camino Real, Suite 101
Santa Clara CALIFORNIA 95050 US
CEO: Jeffrey W. Dunn
Employees: 349
Phone: 14082070700
The current stock price of SIBN is 19.06 USD. The price increased by 3.08% in the last trading session.
The exchange symbol of SI-BONE INC is SIBN and it is listed on the Nasdaq exchange.
SIBN stock is listed on the Nasdaq exchange.
15 analysts have analysed SIBN and the average price target is 25.16 USD. This implies a price increase of 32% is expected in the next year compared to the current price of 19.06. Check the SI-BONE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SI-BONE INC (SIBN) has a market capitalization of 812.15M USD. This makes SIBN a Small Cap stock.
SI-BONE INC (SIBN) currently has 349 employees.
SI-BONE INC (SIBN) has a support level at 18.38 and a resistance level at 19.74. Check the full technical report for a detailed analysis of SIBN support and resistance levels.
The Revenue of SI-BONE INC (SIBN) is expected to grow by 17.65% in the next year. Check the estimates tab for more information on the SIBN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SIBN does not pay a dividend.
SI-BONE INC (SIBN) will report earnings on 2025-08-04, after the market close.
SI-BONE INC (SIBN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.64).
The outstanding short interest for SI-BONE INC (SIBN) is 4.27% of its float. Check the ownership tab for more information on the SIBN short interest.
ChartMill assigns a technical rating of 10 / 10 to SIBN. When comparing the yearly performance of all stocks, SIBN is one of the better performing stocks in the market, outperforming 91.01% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to SIBN. While SIBN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SIBN reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS increased by 41.28% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -11.68% | ||
ROE | -15.87% | ||
Debt/Equity | 0.21 |
ChartMill assigns a Buy % Consensus number of 84% to SIBN. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 15.02% and a revenue growth 17.65% for SIBN